Related Experiment Video
Updated: Jul 21, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Neuroplasticity in Alzheimer's disease
Bruce Teter1, J Wesson Ashford
1Department of Medicine, University of California Los Angeles, California and Veteran's Affairs-Greater Los Angeles Healthcare System, Sepulveda, California 91343, USA.
Journal of Neuroscience Research
|October 23, 2002
Summary
Despite advances, central nervous system (CNS) regeneration remains limited. However, understanding CNS plasticity mechanisms may offer new therapeutic strategies for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Neurobiology
Background:
- Historically, central nervous system (CNS) regeneration was deemed impossible in adults, as per Ramon y Cajal's 1928 decree.
- Modern science acknowledges limited CNS plasticity, particularly in lower brain and primary cortical structures.
- Mechanisms underlying CNS recovery after injury are now recognized.
Purpose of the Study:
- To explore the limitations and potential of CNS regeneration.
- To investigate how CNS recovery mechanisms might relate to neurodegenerative disease vulnerability.
- To identify therapeutic avenues for neurodegenerative conditions.
Main Methods:
- Review of historical and current scientific literature on CNS plasticity and regeneration.
- Analysis of known mechanisms for recovery from CNS injury.
- Exploration of the link between these mechanisms and neurodegenerative processes.
Main Results:
- Ramon y Cajal's assertion on the general immutability of adult CNS nerve paths holds largely true.
- Specific mechanisms facilitating recovery from CNS injury exist.
- These same mechanisms may inadvertently increase susceptibility to neurodegenerative diseases.
Conclusions:
- While complete CNS regeneration remains a future goal, understanding existing plasticity is crucial.
- Exploiting endogenous CNS recovery mechanisms presents a promising therapeutic strategy for neurodegenerative disorders.
- Further research is needed to harness these mechanisms safely and effectively.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:01Neuroplasticity
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...